Drug Voxelotor Sufficient NCIT:C152089 SCDO:1000381 An orally bioavailable modulator and stabilizer of sickle cell hemoglobin (HbS), with potential use in the treatment of sickle cell disease (SCD). Upon administration, voxelotor targets and covalently binds to the N-terminal valine of the alpha chain of HbS. This stabilizes HbS, thereby improving oxygen binding affinity. The binding of voxelotor to HbS prevents HbS polymerization, reduces sickling, decreases red blood cell (RBC) damage and increases the half-life of RBCs. This improves blood flow and decreases hemolytic anemia. Oxbryta Is an accepted therapy for adults and pediatric patients 12 years of age and older with sickle cell disease. GBT440 GBT-440 Preventative Therapeutics